UniProtKB/Swiss-Prot P48643: Variant p.Lys176Arg

T-complex protein 1 subunit epsilon
Gene: CCT5
Feedback?

Variant information Variant position:

176 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:

US The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Lysine (K) to Arginine (R) at position 176 (K176R, p.Lys176Arg). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:

Similar physico-chemical property. Both residues are large size and basic. The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:

2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page
Variant description:

Found in a patient with severe developmental delay, intellectual disability, pyramidal and cerebellar signs, visual impairment, polymicrogyria and pontocerebellar hypoplasia; uncertain significance; the orthologous yeast mutation induces yeast lethality suggesting loss of function. Any additional useful information about the variant.

Sequence information Variant position:

176 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:

541 The length of the canonical sequence.
Location on the sequence:

LVDIKDTEPLIQTAKTTLGS K VVNSCHRQMAEIAVNAVLTV The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         LVDIKD--TEPLIQTAKTTLGSKVVNSCHRQMAEIAVNAVLTV

Mouse                         LVDINN--PEPLIQTAKTTLGSKVINSCHRQMAEIAVNAVL

Rat                           LVDINN--PEPLIQTAKTTLGSKVVNSCHRQMAEIAVNAVL

Caenorhabditis elegans        -FPVEN--RERLVETAQTSLGSKIVNRSLRQFAEIAVDAVL

Slime mold                    EFSKDN--IEPLIKTAMTCLGSKIVNRFHRQMSEIAVKAVI

Baker's yeast                 SASNDELFRDFLLRAAKTSLGSKIVSKDHDRFAEMAVEAVI

Fission yeast                 DFSPEN--TTNLFRSAKTSLGSKVVSKAHDHFANIAVDAVL

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	2 – 541	T-complex protein 1 subunit epsilon
Binding site	175 – 175

Literature citations
Brain malformations and seizures by impaired chaperonin function of TRiC.
Kraft F.; Rodriguez-Aliaga P.; Yuan W.; Franken L.; Zajt K.; Hasan D.; Lee T.T.; Flex E.; Hentschel A.; Innes A.M.; Zheng B.; Julia Suh D.S.; Knopp C.; Lausberg E.; Krause J.; Zhang X.; Trapane P.; Carroll R.; McClatchey M.; Fry A.E.; Wang L.; Giesselmann S.; Hoang H.; Baldridge D.; Silverman G.A.; Radio F.C.; Bertini E.; Ciolfi A.; Blood K.A.; de Sainte Agathe J.M.; Charles P.; Bergant G.; Cuturilo G.; Peterlin B.; Diderich K.; Streff H.; Robak L.; Oegema R.; van Binsbergen E.; Herriges J.; Saunders C.J.; Maier A.; Wolking S.; Weber Y.; Lochmueller H.; Meyer S.; Aleman A.; Polavarapu K.; Nicolas G.; Goldenberg A.; Guyant L.; Pope K.; Hehmeyer K.N.; Monaghan K.G.; Quade A.; Smol T.; Caumes R.; Duerinckx S.; Depondt C.; Van Paesschen W.; Rieubland C.; Poloni C.; Guipponi M.; Arcioni S.; Meuwissen M.; Jansen A.C.; Rosenblum J.; Haack T.B.; Bertrand M.; Gerstner L.; Magg J.; Riess O.; Schulz J.B.; Wagner N.; Wiesmann M.; Weis J.; Eggermann T.; Begemann M.; Roos A.; Haeusler M.; Schedl T.; Tartaglia M.; Bremer J.; Pak S.C.; Frydman J.; Elbracht M.; Kurth I.;
Science 386:516-525(2024)
Cited for: VARIANT ARG-176; INVOLVEMENT IN BRAIN DEVELOPMENTAL DISORDERS; CHARACTERIZATION OF VARIANT ARG-176;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.